Recommended DAA Treatment Regimens
- Clinicians and patients should choose an anti-HCV regimen based on the pretreatment assessment and any previous HCV treatment. (A2)
- Treatment-naive patients, see Tables 2 and 3.
- Patients previously treated with PEG-IFN, see Tables 4 and 5.
- Patients previously treated with DAAs, see Tables 6 and 7.
- See the NYSDOH AI guideline Pretreatment Assessment in Adults With Chronic HCV Infection.
- If a regimen that includes weight-based RBV is prescribed, clinicians should dose as follows (A1):
- <75 kg: RBV 400 mg once daily plus 600 mg once daily (total daily dose: 1,000 mg)
- ≥75 kg: RBV 600 mg twice daily (total daily dose: 1,200 mg)
- In patients with genotype 3 HCV and compensated cirrhosis, clinicians should perform NS5A RAS testing before initiating therapy. (A2)
- Clinicians new to HCV treatment should consult a specialist in treatment of liver disease or viral hepatitis when retreating patients in whom any prior DAA treatment has failed. (B3) Failure is defined as detectable HCV RNA 12 weeks after the conclusion of HCV treatment.
